Barinthus Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Barinthus Biotherapeutics plc
BRNS Stock   1.04  0.03  2.97%   
Barinthus Biotherapeutics financial statements provide useful quarterly and yearly information to potential Barinthus Biotherapeutics plc investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Barinthus Biotherapeutics financial statements helps investors assess Barinthus Biotherapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Barinthus Biotherapeutics' valuation are summarized below:
Gross Profit
-30.1 M
Market Capitalization
41.8 M
Enterprise Value Revenue
0.6155
Revenue
15 M
Earnings Share
(1.49)
There are over one hundred nineteen available fundamental signals for Barinthus Biotherapeutics plc, which can be analyzed over time and compared to other ratios. All traders should validate Barinthus Biotherapeutics' prevailing fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 128.6 M in 2025, whereas Enterprise Value is likely to drop slightly above 13.7 M in 2025.

Barinthus Biotherapeutics Total Revenue

876,185

Check Barinthus Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Barinthus Biotherapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 6.6 M, Interest Expense of 23.9 K or Total Revenue of 876.2 K, as well as many indicators such as Price To Sales Ratio of 193, Dividend Yield of 0.0 or PTB Ratio of 0.54. Barinthus financial statements analysis is a perfect complement when working with Barinthus Biotherapeutics Valuation or Volatility modules.
  
Check out the analysis of Barinthus Biotherapeutics Correlation against competitors.

Barinthus Biotherapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets183.7 M246.7 M89.8 M
Slightly volatile
Short and Long Term Debt Total12.3 M11.7 M7.3 M
Slightly volatile
Other Current Liabilities6.4 M10.6 M3.7 M
Slightly volatile
Total Current Liabilities10.9 M14.5 M7.9 M
Slightly volatile
Property Plant And Equipment Net23.4 M22.3 M7.5 M
Slightly volatile
Accounts Payable2.6 M1.4 M3.5 M
Slightly volatile
Cash133.1 M163.4 M62.8 M
Slightly volatile
Non Current Assets Total38.3 M66.2 M19 M
Slightly volatile
Cash And Short Term Investments133.1 M163.4 M62.8 M
Slightly volatile
Net Receivables7.6 M9.1 M5.4 M
Slightly volatile
Common Stock Total Equity6191.1 K527
Slightly volatile
Common Stock Shares Outstanding32.5 M44.1 M33.2 M
Very volatile
Liabilities And Stockholders Equity183.7 M246.7 M89.8 M
Slightly volatile
Non Current Liabilities Total25.9 M13.4 M32.5 M
Slightly volatile
Capital Lease Obligations15.7 M14.9 M4.9 M
Slightly volatile
Other Current Assets4.6 M7.9 M2.6 M
Slightly volatile
Total Liabilities33.8 M24.8 M40 M
Pretty Stable
Property Plant And Equipment Gross27.9 M26.6 M8.3 M
Slightly volatile
Total Current Assets145.4 M180.4 M70.8 M
Slightly volatile
Capital Stock8121.1 K539
Slightly volatile
Net Working Capital134.5 M166 M62.9 M
Slightly volatile
Short Term Debt2.2 M2.1 M563.7 K
Slightly volatile
Common Stock8121.1 K539
Slightly volatile
Property Plant Equipment2 M1.6 M2.5 M
Slightly volatile
Long Term Debt35.8 M40.2 M43.9 M
Slightly volatile
Other Liabilities8.4 M9.4 M10.3 M
Slightly volatile
Noncontrolling Interest In Consolidated Entity349.6 K393.3 K428.8 K
Slightly volatile
Non Currrent Assets Other976.1 K1 M843.5 K
Slightly volatile
Capital Surpluse295.3 M332.2 M362.2 M
Slightly volatile
Short and Long Term Debt127.2 K143.1 K156 K
Slightly volatile
Non Current Liabilities Other2.7 M2.8 M13.5 M
Slightly volatile
Intangible Assets22.6 M22.6 M29.7 M
Slightly volatile
Inventory0.80.90.9813
Slightly volatile

Barinthus Biotherapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization6.6 M6.3 M1.8 M
Slightly volatile
Interest Expense23.9 K25.2 K481.1 K
Pretty Stable
Total Revenue876.2 K922.3 K7.6 M
Very volatile
Gross Profit876.2 K922.3 K7.6 M
Very volatile
Other Operating Expenses50.1 M97.4 M41.8 M
Slightly volatile
Research Development30.8 M47.6 M30.5 M
Pretty Stable
Total Operating Expenses50.1 M97.4 M41.6 M
Slightly volatile
Interest Income4.4 M4.2 M956 K
Slightly volatile
Selling General Administrative48.1 M45.8 M17.5 M
Slightly volatile
Reconciled Depreciation6.2 M5.9 M1.5 M
Slightly volatile
Selling And Marketing Expenses123.5 K139 K151.5 K
Slightly volatile

Barinthus Biotherapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings33 M37.1 M40.5 M
Slightly volatile
Begin Period Cash Flow234.7 M223.5 M75.3 M
Slightly volatile
Depreciation6.6 M6.2 M1.7 M
Slightly volatile
Capital Expenditures6.5 M6.2 M1.7 M
Slightly volatile
Total Cash From Financing Activities1.6 M1.7 M16.9 M
Pretty Stable
End Period Cash Flow133.1 M163.4 M62.8 M
Slightly volatile
Change To Liabilities1.2 M800.1 K2.3 M
Slightly volatile
Stock Based Compensation7 M4.5 M5.2 M
Slightly volatile
Issuance Of Capital Stock2.1 M2.2 M14.7 M
Pretty Stable
Sale Purchase Of Stock80.5 M90.5 M98.7 M
Slightly volatile
Change Receivables447.2 K503.1 K548.5 K
Slightly volatile
Cash And Cash Equivalents Changes141.8 M159.5 M173.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio193203132
Slightly volatile
Days Sales Outstanding2.2 K3.3 K1.3 K
Slightly volatile
Average Payables3.4 M3.8 M4.2 M
Slightly volatile
Stock Based Compensation To Revenue6.897.255.6534
Slightly volatile
Capex To Depreciation1.021.280.7595
Slightly volatile
Sales General And Administrative To Revenue29.1444.7115.0817
Slightly volatile
Research And Ddevelopement To Revenue48.846.4715.9256
Slightly volatile
Capex To Revenue6.386.071.4913
Slightly volatile
Cash Per Share4.044.26626
Slightly volatile
Intangibles To Total Assets0.130.160.1561
Pretty Stable
Current Ratio9.4811.216.5869
Slightly volatile
Receivables Turnover0.110.121.4446
Slightly volatile
Graham Number15.816.631.8 K
Slightly volatile
Capex Per Share0.150.164.2682
Slightly volatile
Average Receivables3.5 M4.6 M3.9 M
Slightly volatile
Revenue Per Share0.02280.02469.6435
Slightly volatile
Interest Debt Per Share0.370.39721
Slightly volatile
Debt To Assets0.06610.06960.1314
Very volatile
Operating Cycle2.2 K3.3 K1.3 K
Slightly volatile
Long Term Debt To Capitalization4.835.445.9295
Slightly volatile
Quick Ratio9.4811.216.5869
Slightly volatile
Net Income Per E B T1.620.861.3027
Slightly volatile
Cash Ratio8.6410.155.6668
Slightly volatile
Cash Conversion Cycle3.9 K4.2 K1.6 B
Slightly volatile
Days Of Sales Outstanding2.2 K3.3 K1.3 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.91.01.0351
Pretty Stable
Fixed Asset Turnover0.04520.04751.8346
Slightly volatile
Debt Ratio0.06610.06960.1314
Very volatile
Price Sales Ratio193203132
Slightly volatile
Asset Turnover0.00410.00430.2427
Slightly volatile

Barinthus Biotherapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap128.6 M127.5 M56.6 M
Slightly volatile

Barinthus Fundamental Market Drivers

Cash And Short Term Investments142.1 M

Barinthus Upcoming Events

22nd of March 2024
Upcoming Quarterly Report
View
10th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Barinthus Biotherapeutics Financial Statements

Barinthus Biotherapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Barinthus Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Barinthus Biotherapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Barinthus Biotherapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Total Revenue922.3 K876.2 K
Cost Of Revenue3.6 K3.8 K
Stock Based Compensation To Revenue 7.25  6.89 
Sales General And Administrative To Revenue 44.71  29.14 
Research And Ddevelopement To Revenue 46.47  48.80 
Capex To Revenue 6.07  6.38 
Revenue Per Share 0.02  0.02 
Ebit Per Revenue(120.33)(126.34)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Barinthus Stock Analysis

When running Barinthus Biotherapeutics' price analysis, check to measure Barinthus Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Barinthus Biotherapeutics is operating at the current time. Most of Barinthus Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Barinthus Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Barinthus Biotherapeutics' price. Additionally, you may evaluate how the addition of Barinthus Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY